期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

OPG/RANKL/RANK轴在骨相关疾病中的研究现状 被引量：3

原文传递
导出
摘要 OPG／RANKL／RNAK轴作为一个信号转导通路，在许多疾病的发生发展中都具有重要的作用，因此也成为国内外的一个研究热点。各种骨相关性疾病，特别是恶性肿瘤的骨转移导致的骨破坏，是严重影响患者生活质量及生存率的重要因素，0PG／RANKL／RANK轴作为各种导致骨质破坏因素的最终通路，在骨相关疾病的研究中具有重要地位，本文对近几年的相关研究进展做一综述。
作者 王华贝
机构地区 西安一四一医院老年病科
出处 《中国临床研究》 CAS 2012年第1期80-81,共2页 Chinese Journal of Clinical Research
关键词 骨相关疾病 骨保护素(OPG) 核因子-κB受体活化因子配体(RANKL) 核因子-κB受体活化因子(RANK)
分类号 R681 [医药卫生—骨科学]
  • 相关文献

参考文献19

  • 1Liu XH, Kirschenbaum A, Yao S, et al. Cross-Talk between the in- terleukin-6 and prostaglandin E (2) signaling systems results in en- hancement of osteoclastogenesis through effects on the osteoprote- gerin/receptor activator of nuclear factor-KB (RANK) ligand/ RANK system[J]. Endocrinology,2005,146(4) : 1991 - 1998.
  • 2Bord S, Frith E, Ireland DC, et al. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by estrogen [ J ]. Brit J Haemato1,2004,126(2) :244 - 251.
  • 3Trofimov S, Pantsulaia I, Kobyliansky E, et al. Circulating levels of receptor activator of nuclear factor-KB ligand/osteoprotegerin/mae- rophage-colony stimulating factor in a presumably healthy humanpopulation [ J ]. Eur J Endoerinol,2004,150 (3) :305 - 311.
  • 4Uemura H, Yasui T, Umino Y, et al. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover [ J ]. Bone, 2003,33 (5) :860-866.
  • 5Abdallah BM, Stilgren LS, Nissen N,et al. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures [J]. Calcif Tissue Int,2005,76(2) :90 -97.
  • 6Nabipour I, Kalantarhormozi M, Larijani B, et al. Osteoprotegerin in relation to type 2 diabetes meltitus and the metabolic syndrome in postmenopausal women [ J ]. Metabolism,2010,59 ( 5 ) : 742 -747.
  • 7Catrina AI, af Klint E, Emestam S, et al Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis [ J ]. Arthritis Rheum,2006,54 ( 1 ) :76 - 81.
  • 8Ho TY, Santora K, Chen JC, et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin( OPG), in rat adjuvant-induced ar- thritis[J].-Bone,2011,48(6) :1346 - 1353.
  • 9Ahinova AE,Torumer F, Akturk M, et al. Re|ationship between ser- um osteoprotegerin, glycemie control, renal function and markers of atherosclerosis in type 2 diabetes [J]. Scand J Clin Lab Invest, 2011,71 (4) :340 -343.
  • 10Mabilleau G, Petrova NL, Edmonds ME, et al. Increased ostcoclastic activity in acute Charcot's osteoarthropathy:the role of receptor acti- vator of nuclear factor-kappaB ligand [ J ]. Diabetoloqia, 2008,51 (6) :1035 - 1040.

二级参考文献63

  • 1PARKIN DM, BRAY F, FERLAY J, et al. Global cancer statistics, 2002 J[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 2I BOYLE W J, SIMONET WS, LACEY DL. Osteoclast differentiation and activation[J]. Nature, 2003, 423: 337-342.
  • 3KIM Y, LEE Y, KIM H, et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation and phospholipase C (PLC) in human endothelial cells[J].J Biol Chem, 2002, 277: 6799-6805.
  • 4ATKINS D, REIFFEN KA, TEGTMEIER CL, et al. Immunohistochemical detection of EGFR in paraffinembedded tumor tissues variation in staining intensity due to choice of fixative and storage time of tissue sections[J]. J Histochem Cytochem, 2004, 52 (7): 893-901.
  • 5WEINDER N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147: 9-19.
  • 6HERBST RS. Therapeutic options to target angiogenesis in human malignancies[J]. Expert Opinion on Emerging Drugs, 2006, 11: 635-665.
  • 7LI Y, KUCUK O, HUSSAIN M. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegefin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer [J]. Cancer Res, 2006, 66(9): 4816-4825.
  • 8WILLIAM C, DOUGALL, MICHELLE CHAISSONE. The RANK/RANKL/OPG triad in cancer-induced bone diseases [J]. Cancer Metastasis Rev, 2006, 25: 541-549.
  • 9TANAKA F, OTAKE Y, YANAGGIHARA K, et al. Evaluation of angiogenesis in non-smaU cell lung cancer:comparison between anti-CD34 antibody and anti-CD105 antibody[J]. Clin Cancer Res, 2001, 7(11): 3410-3415.
  • 10YANG H, LI M, CHAI H, et al. Expression and regulation of neuropilins and VEGF receptors by TNF-α in human endothehal cells[J]. Journal of Surgical Research, 2004, 122: 249-255.

共引文献15

同被引文献44

引证文献3

二级引证文献9

中国临床研究
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部